Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | MAX | P61244 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14713013 | 0.76 | MYC (0.47) | MYCMAXALOX15PTGS2 | |
| SCHEMBL20738021 | 0.65 | MYC (0.38) | MYCMAXALOX15PTGS2 | |
| SCHEMBL9007677 | 0.63 | MYC (0.46) | MYCMAXALOX15PTGS2 | |
| SCHEMBL9007679 | 0.63 | MYC (0.46) | MYCMAXALOX15PTGS2 | |
| SCHEMBL28305494 | 0.61 | PTPRC (0.46) | ALOX15 | |
| SCHEMBL3084677 | 0.61 | ALDH1A1 (0.38) | MYCMAX | |
| SCHEMBL12961158 | 0.60 | MYC (0.70) | MYCMAXALOX15PTGS2 | |
| SCHEMBL19546338 | 0.59 | ALDH1A1 (0.52) | MYCMAX | |
| SCHEMBL19546339 | 0.59 | ALDH1A1 (0.52) | MYCMAX | |
| SCHEMBL15888512 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAX | MYC 397/4885MAX 4172/4885ALOX15 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.